Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0ZN3M
|
|||
| Drug Name |
PMID27998201-Compound-19
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Patented | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H33BrN2O6S
|
|||
| Canonical SMILES |
CC(C)CC(C=CS(=O)(=O)OC1=CC=C(C=C1)Br)NC(=O)C(CC2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3
|
|||
| InChI |
1S/C30H33BrN2O6S/c1-22(2)19-26(17-18-40(36,37)39-27-15-13-25(31)14-16-27)32-29(34)28(20-23-9-5-3-6-10-23)33-30(35)38-21-24-11-7-4-8-12-24/h3-18,22,26,28H,19-21H2,1-2H3,(H,32,34)(H,33,35)/b18-17+/t26-,28+/m1/s1
|
|||
| InChIKey |
FMZWJWZKFKZMSS-FMPLDUIVSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin L (CTSL) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Cathepsin L (CTSL) | Target's Patent Info | [1] | |
| KEGG Pathway | Lysosome | |||
| Phagosome | ||||
| Antigen processing and presentation | ||||
| Proteoglycans in cancer | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Reactome | Endosomal/Vacuolar pathway | |||
| Collagen degradation | ||||
| Degradation of the extracellular matrix | ||||
| Trafficking and processing of endosomal TLR | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| MHC class II antigen presentation | ||||
| WikiPathways | Primary Focal Segmental Glomerulosclerosis FSGS | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.